 |
市场调查报告书
商品编码
1421092
全球抗焦虑药物市场研究报告 - 2024 年至 2032 年产业分析、规模、份额、成长、趋势与预测Global Anti-Anxiety Drug Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032 |
||||||
全球抗焦虑药物市场需求预计将从 2023 年的 157.4 亿美元达到近 250.1 亿美元的市场规模，2024-2032 年研究期间复合CAGR为 5.28%。
抗焦虑药，也称为抗焦虑药，是一种旨在缓解焦虑症症状的药物。这些疾病是一种以过度担忧、恐惧或紧张为特征的精神健康状况，通常会导致严重的痛苦或日常功能受损。这些药物透过影响中枢神经系统来减轻焦虑症状的强度。
市场动态
抗焦虑药物市场是由几个相互关联的因素所推动的。全球对心理健康问题的认识和接受度不断提高，加上焦虑症盛行率不断上升，导致抗焦虑药物的需求不断增长。药物研究和开发的不断进步导致新化合物和製剂的发现，从而增强了这些药物的有效性。全球人口老化的特征是对焦虑症的敏感度更高，这进一步推动了市场的成长。此外，压力水平升高的现代生活方式、不断扩大的医疗基础设施以及支持心理健康研究的不断变化的监管环境都有助于市场的扩张。处方率的提高和远距医疗和数位医疗等治疗方式的技术进步也发挥关键作用。然而，挑战包括对过度处方、潜在副作用的担忧，以及需要包括治疗和生活方式介入在内的全面心理健康方法。
研究报告涵盖波特五力模型、市场吸引力分析和价值链分析。这些工具有助于清晰地了解行业结构并评估全球范围内的竞争吸引力。此外，这些工具也对全球抗焦虑药物市场的各个细分市场进行了包容性评估。抗焦虑药物产业的成长和趋势为本研究提供了整体方法。
市场区隔
抗焦虑药物市场报告的这一部分提供了国家和区域层面细分市场的详细资料，从而帮助策略师确定相应产品或服务的目标人群以及即将到来的机会。
按药物类别
- 选择性血清素再摄取抑制剂 (SSRI)
- 苯二氮平类
- 血清素-正肾上腺素再摄取抑制剂 (SNRI)
- β受体阻断剂
按配销通路
- 医院药房
- 零售药局/药局
- 网路药局
区域分析
本节涵盖区域前景，重点介绍北美、欧洲、亚太地区、拉丁美洲以及中东和非洲抗焦虑药物市场当前和未来的需求。此外，该报告重点关注所有主要地区各个应用领域的需求、估计和预测。
该研究报告还涵盖了市场主要参与者的全面概况以及对全球竞争格局的深入了解。抗焦虑药物市场的主要参与者包括辉瑞公司、礼来公司、葛兰素史克公司、强生公司、阿斯特捷利康公司、罗氏控股公司、森林实验室（艾尔建的子公司，现为艾伯维的一部分）、百时美施贵宝施贵宝公司、赛诺菲公司、灵北公司。本节包含竞争格局的整体视图，包括各种策略发展，例如关键併购、未来产能、合作伙伴关係、财务概况、合作、新产品开发、新产品发布和其他发展。
如果您有任何客製化要求，请写信给我们。我们的研究团队可以根据您的需求提供客製化报告。
目录
第一章：前言
- 报告说明
- 客观的
- 目标受众
- 独特的销售主张 (USP) 和产品
- 研究范围
- 研究方法论
- 市场研究过程
- 市场研究方法论
第 2 章：执行摘要
- 市集亮点
- 全球市场概况
第 3 章：抗焦虑药物 - 产业分析
- 简介 - 市场动态
- 市场驱动因素
- 市场限制
- 机会
- 产业动态
- 波特五力分析
- 市场吸引力分析
- 按药品类别分類的市场吸引力分析
- 按配销通路分類的市场吸引力分析
- 市场吸引力分析：按地区
第 4 章：价值链分析
- 价值链分析
- 原料分析
- 原料清单
- 原料厂商清单
- 主要原物料价格走势
- 潜在买家名单
- 行销管道
- 直效行销
- 间接行销
- 行销通路发展趋势
第 5 章：全球抗焦虑药物市场分析：按药物类别
- 按药物类别概述
- 历史和预测数据
- 按药物类别分析
- 选择性血清素再摄取抑制剂 (SSRI)
- 苯二氮平类
- 血清素-正肾上腺素再摄取抑制剂 (SNRI)
- β受体阻断剂
第 6 章：全球抗焦虑药物市场分析：按分销管道
- 按配销通路分類的概览
- 历史和预测数据
- 按配销通路分析
- 医院药房
- 零售药局/药局
- 网路药局
第 7 章：全球抗焦虑药物市场分析：依地理位置
- 区域展望
- 介绍
- 北美销售分析
- 概览、历史与预测资料销售分析
- 北美按细分市场销售分析
- 北美按国家销售分析
- 美国销售分析
- 加拿大销售分析
- 墨西哥销售分析
- 欧洲销售分析
- 概览、历史与预测资料销售分析
- 欧洲按细分市场销售分析
- 欧洲按国家销售分析
- 英国销售分析
- 法国销售分析
- 德国销售分析
- 义大利销售分析
- 俄罗斯销售分析
- 欧洲其他地区销售分析
- 亚太地区销售分析
- 概览、历史与预测资料销售分析
- 亚太地区按细分市场销售分析
- 亚太地区国家/地区销售分析
- 中国销售分析
- 印度销售分析
- 日本销售分析
- 韩国销售分析
- 澳洲销售分析
- 东南亚销售分析
- 亚太地区其他地区销售分析
- 拉丁美洲销售分析
- 概览、历史与预测资料销售分析
- 拉丁美洲按细分市场销售分析
- 拉丁美洲按国家销售分析
- 巴西销售分析
- 阿根廷销售分析
- 秘鲁销售分析
- 智利销售分析
- 拉丁美洲其他地区销售分析
- 中东和非洲销售分析
- 概览、历史与预测资料销售分析
- 中东和非洲按细分市场销售分析
- 中东和非洲国家销售分析
- 沙乌地阿拉伯销售分析
- 阿联酋销售分析
- 以色列销售分析
- 南非销售分析
- 中东其他地区和非洲销售分析
第 8 章：抗焦虑药物公司的竞争格局
- 抗焦虑药物市场竞争
- 伙伴关係/协作/协议
- 併购
- 新产品发布
- 其他发展
第 9 章：公司简介
- 顶级公司市占率分析
- 市场集中度
- Pfizer Inc.
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Eli Lilly and Company
- 公司简介
- 公司收入
- 产品
- 最近的发展
- GlaxoSmithKline plc
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Johnson & Johnson
- 公司简介
- 公司收入
- 产品
- 最近的发展
- AstraZeneca plc
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Roche Holding AG
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Forest Laboratories (a subsidiary of Allergan
- 公司简介
- 公司收入
- 产品
- 最近的发展
- now part of AbbVie)
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Bristol Myers Squibb Company
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Sanofi SA
- 公司简介
- 公司收入
- 产品
- 最近的发展
- Lundbeck A/S
- 公司简介
- 公司收入
- 产品
- 最近的发展
註 - 在公司概况中，财务详细资料和近期发展视情况而定，或者如果是私人公司，则可能不包括在内
The global demand for Anti-Anxiety Drug Market is presumed to reach the market size of nearly USD 25.01 Billion by 2032 from USD 15.74 Billion in 2023 with a CAGR of 5.28% under the study period 2024 - 2032.
Anti-anxiety drugs, also known as anxiolytics, are medications designed to relieve symptoms of anxiety disorders. These disorders are mental health conditions characterized by excessive worry, fear, or nervousness, often leading to significant distress or impairment in daily functioning. These drugs work by affecting the central nervous system to reduce the intensity of anxiety symptoms.
MARKET DYNAMICS
The anti-anxiety drug market is propelled by several interconnected factors. Rising global awareness and acceptance of mental health issues, coupled with an increasing prevalence of anxiety disorders, contribute to a growing demand for anti-anxiety medications. Ongoing advancements in pharmaceutical research and development lead to the discovery of novel compounds and formulations, enhancing the effectiveness of these medications. The aging global population, characterized by a higher susceptibility to anxiety disorders, further boosts market growth. Additionally, modern lifestyles with elevated stress levels, expanding healthcare infrastructure, and changing regulatory environments supporting mental health research contribute to the market's expansion. Increased prescription rates and technological advancements in treatment modalities, such as telemedicine and digital health, also play pivotal roles. However, challenges include concerns about over-prescription, potential side effects, and the need for a comprehensive mental health approach encompassing therapy and lifestyle interventions.
The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of anti-anxiety drug. The growth and trends of anti-anxiety drug industry provide a holistic approach to this study.
MARKET SEGMENTATION
This section of the anti-anxiety drug market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.
By Drug Class
- Selective Serotonin Reuptake Inhibitors (SSRIs)
- Benzodiazepines
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
- Beta Blockers
By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies/Drug Stores
- Online Pharmacies
REGIONAL ANALYSIS
This section covers the regional outlook, which accentuates current and future demand for the Anti-Anxiety Drug market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.
The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Anti-Anxiety Drug market include Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline plc, Johnson & Johnson, AstraZeneca plc, Roche Holding AG, Forest Laboratories (a subsidiary of Allergan, now part of AbbVie), Bristol Myers Squibb Company, Sanofi S.A., Lundbeck A/S. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.
In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.
TABLE OF CONTENTS
1 . PREFACE
- 1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
- 1.2. Research Scope
- 1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology
2 . EXECUTIVE SUMMARY
- 2.1. Highlights of Market
- 2.2. Global Market Snapshot
3 . ANTI-ANXIETY DRUG - INDUSTRY ANALYSIS
- 3.1. Introduction - Market Dynamics
- 3.2. Market Drivers
- 3.3. Market Restraints
- 3.4. Opportunities
- 3.5. Industry Trends
- 3.6. Porter's Five Force Analysis
- 3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Drug Class
- 3.7.2 Market Attractiveness Analysis By Distribution Channel
- 3.7.3 Market Attractiveness Analysis By Region
4 . VALUE CHAIN ANALYSIS
- 4.1. Value Chain Analysis
- 4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
- 4.3. List of Potential Buyers
- 4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend
5 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DRUG CLASS
- 5.1 Overview by Drug Class
- 5.2 Historical and Forecast Data
- 5.3 Analysis by Drug Class
- 5.4 Selective Serotonin Reuptake Inhibitors (SSRIs) Historic and Forecast Sales by Regions
- 5.5 Benzodiazepines Historic and Forecast Sales by Regions
- 5.6 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Historic and Forecast Sales by Regions
- 5.7 Beta Blockers Historic and Forecast Sales by Regions
6 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY DISTRIBUTION CHANNEL
- 6.1 Overview by Distribution Channel
- 6.2 Historical and Forecast Data
- 6.3 Analysis by Distribution Channel
- 6.4 Hospital Pharmacies Historic and Forecast Sales by Regions
- 6.5 Retail Pharmacies/Drug Stores Historic and Forecast Sales by Regions
- 6.6 Online Pharmacies Historic and Forecast Sales by Regions
7 . GLOBAL ANTI-ANXIETY DRUG MARKET ANALYSIS BY GEOGRAPHY
- 7.1. Regional Outlook
- 7.2. Introduction
- 7.3. North America Sales Analysis
- 7.3.1. Overview, Historic and Forecast Data Sales Analysis
- 7.3.2. North America By Segment Sales Analysis
- 7.3.3. North America By Country Sales Analysis
- 7.3.4. United State Sales Analysis
- 7.3.5. Canada Sales Analysis
- 7.3.6. Mexico Sales Analysis
- 7.4. Europe Sales Analysis
- 7.4.1. Overview, Historic and Forecast Data Sales Analysis
- 7.4.2. Europe by Segment Sales Analysis
- 7.4.3. Europe by Country Sales Analysis
- 7.4.4. United Kingdom Sales Analysis
- 7.4.5. France Sales Analysis
- 7.4.6. Germany Sales Analysis
- 7.4.7. Italy Sales Analysis
- 7.4.8. Russia Sales Analysis
- 7.4.9. Rest Of Europe Sales Analysis
- 7.5. Asia Pacific Sales Analysis
- 7.5.1. Overview, Historic and Forecast Data Sales Analysis
- 7.5.2. Asia Pacific by Segment Sales Analysis
- 7.5.3. Asia Pacific by Country Sales Analysis
- 7.5.4. China Sales Analysis
- 7.5.5. India Sales Analysis
- 7.5.6. Japan Sales Analysis
- 7.5.7. South Korea Sales Analysis
- 7.5.8. Australia Sales Analysis
- 7.5.9. South East Asia Sales Analysis
- 7.5.10. Rest Of Asia Pacific Sales Analysis
- 7.6. Latin America Sales Analysis
- 7.6.1. Overview, Historic and Forecast Data Sales Analysis
- 7.6.2. Latin America by Segment Sales Analysis
- 7.6.3. Latin America by Country Sales Analysis
- 7.6.4. Brazil Sales Analysis
- 7.6.5. Argentina Sales Analysis
- 7.6.6. Peru Sales Analysis
- 7.6.7. Chile Sales Analysis
- 7.6.8. Rest of Latin America Sales Analysis
- 7.7. Middle East & Africa Sales Analysis
- 7.7.1. Overview, Historic and Forecast Data Sales Analysis
- 7.7.2. Middle East & Africa by Segment Sales Analysis
- 7.7.3. Middle East & Africa by Country Sales Analysis
- 7.7.4. Saudi Arabia Sales Analysis
- 7.7.5. UAE Sales Analysis
- 7.7.6. Israel Sales Analysis
- 7.7.7. South Africa Sales Analysis
- 7.7.8. Rest Of Middle East And Africa Sales Analysis
8 . COMPETITIVE LANDSCAPE OF THE ANTI-ANXIETY DRUG COMPANIES
- 8.1. Anti-Anxiety Drug Market Competition
- 8.2. Partnership/Collaboration/Agreement
- 8.3. Merger And Acquisitions
- 8.4. New Product Launch
- 8.5. Other Developments
9 . COMPANY PROFILES OF ANTI-ANXIETY DRUG INDUSTRY
- 9.1. Top Companies Market Share Analysis
- 9.2. Market Concentration Rate
- 9.3. Pfizer Inc.
- 9.3.1. Company Overview
- 9.3.2. Company Revenue
- 9.3.3. Products
- 9.3.4. Recent Developments
- 9.4. Eli Lilly and Company
- 9.4.1. Company Overview
- 9.4.2. Company Revenue
- 9.4.3. Products
- 9.4.4. Recent Developments
- 9.5. GlaxoSmithKline plc
- 9.5.1. Company Overview
- 9.5.2. Company Revenue
- 9.5.3. Products
- 9.5.4. Recent Developments
- 9.6. Johnson & Johnson
- 9.6.1. Company Overview
- 9.6.2. Company Revenue
- 9.6.3. Products
- 9.6.4. Recent Developments
- 9.7. AstraZeneca plc
- 9.7.1. Company Overview
- 9.7.2. Company Revenue
- 9.7.3. Products
- 9.7.4. Recent Developments
- 9.8. Roche Holding AG
- 9.8.1. Company Overview
- 9.8.2. Company Revenue
- 9.8.3. Products
- 9.8.4. Recent Developments
- 9.9. Forest Laboratories (a subsidiary of Allergan
- 9.9.1. Company Overview
- 9.9.2. Company Revenue
- 9.9.3. Products
- 9.9.4. Recent Developments
- 9.10. now part of AbbVie)
- 9.10.1. Company Overview
- 9.10.2. Company Revenue
- 9.10.3. Products
- 9.10.4. Recent Developments
- 9.11. Bristol Myers Squibb Company
- 9.11.1. Company Overview
- 9.11.2. Company Revenue
- 9.11.3. Products
- 9.11.4. Recent Developments
- 9.12. Sanofi S.A.
- 9.12.1. Company Overview
- 9.12.2. Company Revenue
- 9.12.3. Products
- 9.12.4. Recent Developments
- 9.13. Lundbeck A/S
- 9.13.1. Company Overview
- 9.13.2. Company Revenue
- 9.13.3. Products
- 9.13.4. Recent Developments
Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies
LIST OF TABLES
- Market Snapshot
- Drivers : Impact Analysis
- Restraints : Impact Analysis
- List of Raw Material
- List of Raw Material Manufactures
- List of Potential Buyers
- Analysis by Drug Class (USD MN)
- Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
- Benzodiazepines Market Sales by Geography (USD MN)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
- Beta Blockers Market Sales by Geography (USD MN)
- Analysis Market by Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales by Geography (USD MN)
- Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
- Online Pharmacies Market Sales by Geography (USD MN)
- Global Anti-Anxiety Drug Market Sales by Geography (USD MN)
- North America Market Analysis (USD MN)
- United State Market Analysis (USD MN)
- Canada Market Analysis (USD MN)
- Mexico Market Analysis (USD MN)
- Europe Market Analysis (USD MN)
- Europe Market Estimate by Country (USD MN)
- United Kingdom Market Analysis (USD MN)
- France Market Analysis (USD MN)
- Germany Market Analysis (USD MN)
- Italy Market Analysis (USD MN)
- Russia Market Analysis (USD MN)
- Spain Market Analysis (USD MN)
- Rest of Europe Market Analysis (USD MN)
- Asia Pacific Market Analysis (USD MN)
- China Market Analysis (USD MN)
- Japan Market Analysis (USD MN)
- India Market Analysis (USD MN)
- South Korea Market Analysis (USD MN)
- Australia Market Analysis (USD MN)
- South East Asia Market Analysis (USD MN)
- Rest of Asia Pacific Market Analysis (USD MN)
- Latin America Market Analysis (USD MN)
- Brazil Market Analysis (USD MN)
- Argentina Market Analysis (USD MN)
- Peru Market Analysis (USD MN)
- Chile Market Analysis (USD MN)
- Rest of Latin America Market Analysis (USD MN)
- Middle East & Africa Market Analysis (USD MN)
- Saudi Arabia Market Analysis (USD MN)
- UAE Market Analysis (USD MN)
- Israel Market Analysis (USD MN)
- South Africa Market Analysis (USD MN)
- Rest of Middle East and Africa Market Analysis (USD MN)
- Partnership/Collaboration/Agreement
- Mergers And Acquisition
LIST OF FIGURES
- Research Scope of Anti-Anxiety Drug Report
- Market Research Process
- Market Research Methodology
- Global Anti-Anxiety Drug Market Size, by Region (USD MN)
- Porters Five Forces Analysis
- Market Attractiveness Analysis by Drug Class
- Market Attractiveness Analysis by Distribution Channel
- Market Attractiveness Analysis by Region
- Value Chain Analysis
- Global Market Analysis by Drug Class (USD MN)
- Selective Serotonin Reuptake Inhibitors (SSRIs) Market Sales by Geography (USD MN)
- Benzodiazepines Market Sales by Geography (USD MN)
- Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Market Sales by Geography (USD MN)
- Beta Blockers Market Sales by Geography (USD MN)
- Global Market Analysis by Distribution Channel (USD MN)
- Hospital Pharmacies Market Sales by Geography (USD MN)
- Retail Pharmacies/Drug Stores Market Sales by Geography (USD MN)
- Online Pharmacies Market Sales by Geography (USD MN)
- Global Market Sales (USD MN)
- North America Market Sales (USD MN)
- Europe Market Sales (USD MN)
- Asia Pacific Market Sales (USD MN)
- Latin America Market Sales (USD MN)
- Middle East & Africa Market Sales (USD MN)
- Recent Development in Industry
- Top Companies Market Share Analysis
